| Symbol | CABA |
|---|---|
| Name | CABALETTA BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2929 ARCH STREET,SUITE 600, PHILADELPHIA, Pennsylvania, 19104, United States |
| Telephone | +1 267 759-3100 |
| Fax | — |
| — | |
| Website | https://www.cabalettabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers. Additional info from NASDAQ: |
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Read moreNew Form ARS - Cabaletta Bio, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183571 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183564 <b>Size:</b> 470 KB
Read moreNew Form DEF 14A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-183557 <b>Size:</b> 3 MB
Read moreCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Read moreCabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Read moreNew Form PRE 14A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-160326 <b>Size:</b> 3 MB
Read moreFirst Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares Automated Cell Shuttle™ Platform
Read moreCabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Read more